Author

Maria Matsangou

Observed names: M. Matsangou, Matsangou, Maria

Institution: Astellas Pharma (United States)

Observed institutions: Northwestern University, Atrium Health Wake Forest Baptist, Memorial Sloan Kettering Cancer Center, University of Miami, University of Antwerp, Queen Mary University of London, University of California, San Francisco, Université Paris-Saclay, Marqués de Valdecilla University Hospital, Instituto de Investigación Marqués de Valdecilla, Dana-Farber Cancer Institute, Northwestern Medicine, Sylvester Comprehensive Cancer Center, Astellas Pharma (United States), UCSF Helen Diller Family Comprehensive Cancer Center, Wake Forest Baptist Comprehensive Cancer Center, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Wake Forest University Health Sciences, Wake Forest University

OpenAlex ID: A5081368898

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

2021 · Thomas Powles, Jonathan E. Rosenberg, et al. · New England Journal of Medicine · 1,231

PDF

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application

2016 · Young Kwang Chae, Keerthi Ranganath, et al. · Oncotarget · 298

A Monoclonal Antibody against Wnt-1 Induces Apoptosis in Human Cancer Cells

2004 · Biao He, Liang You, et al. · Neoplasia · 270

PDF

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

2023 · J.E. Rosenberg, T. Powles, et al. · Annals of Oncology · 171

PDF

Biomarkers for PD-1/PD-L1 Blockade Therapy in Non–Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?

2016 · Young Kwang Chae, Alan Pan, et al. · Clinical Lung Cancer · 112

Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA

2016 · Young Kwang Chae, Andrew A. Davis, et al. · Oncotarget · 111

PDF

Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma

2024 · Kohei Shitara, Manish A. Shah, et al. · New England Journal of Medicine · 100

PDF

Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

2024 · Kohei Shitara, Rui-Hua Xu, et al. · Gastric Cancer · 90

Cloning and characterization of a functional promoter of the human SOCS-3 gene

2003 · Biao He, Liang You, et al. · Biochemical and Biophysical Research Communications · 68

Quercetin Enhances the Anti-Tumor Effects of BET Inhibitors by Suppressing hnRNPA1

2019 · Thao N.D. Pham, Sophie Stempel, et al. · International Journal of Molecular Sciences · 58

PDF

Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma

2022 · Nobuaki Matsubara, Junji Yonese, et al. · Cancer Medicine · 55

Retrospective analysis of the impact of HPV status and smoking on mucositis in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemotherapy and radiotherapy

2014 · M. Vatca, J.T. Lucas, et al. · Oral Oncology · 48

Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer

2018 · Young Kwang Chae, Wooyoung M. Choi, et al. · Scientific Reports · 47

PDF

Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors

2024 · Mei Tang, Amit Garg, et al. · Clinical Pharmacokinetics · 45

PDF

2024 · F. Lordick, E. Van Cutsem, et al. · ESMO Open · 29

PDF

Nodal Signaling as a Developmental Therapeutics Target in Oncology

2017 · Aparna Kalyan, Benedito A. Carneiro, et al. · Molecular Cancer Therapeutics · 29

Induction of MNK Kinase–dependent eIF4E Phosphorylation by Inhibitors Targeting BET Proteins Limits Efficacy of BET Inhibitors

2018 · Thao N.D. Pham, Krishan Kumar, et al. · Molecular Cancer Therapeutics · 26

Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW).

2023 · Kohei Shitara, Rui-Hua Xu, et al. · Journal of Clinical Oncology · 22

Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.

2022 · Jonathan E. Rosenberg, Thomas Powles, et al. · Journal of Clinical Oncology · 22

Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review

2018 · Young Kwang Chae, Lauren Chiec, et al. · Oncotarget · 21

PDF

Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer

2016 · Young Kwang Chae, Alan Pan, et al. · Clinical Lung Cancer · 21

First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

2026 · Kohei Shitara, Hirokazu Shoji, et al. · Nature Medicine · 18

PDF

Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab + chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies.

2024 · Kohei Shitara, Rupesh Pophale, et al. · Journal of Clinical Oncology · 18

Population Pharmacokinetic Modeling and Exposure–Response Analysis for the Antibody–Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma

2024 · Peiying Zuo, Peter Bonate, et al. · Clinical Pharmacology & Therapeutics · 17

PDF

Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.

2024 · Kohei Shitara, Eric Van Cutsem, et al. · Journal of Clinical Oncology · 16

PDF

Works count: 74

Citation count: 3,079

H-index: 21

I10-index: 30